APARTES PHARMACEUTICALS

Lobbying client · Ontario · filed 2026 to 2026

A leading North American pharma company with innovative new products.

$290,000 Reported spend

2 Filings counted

1 Firms hired

0 Bills named

Spend is reported income plus in-house expenses across 2 filings. Everything on this page is grouped by the client's LDA id (73317), not by name.

Firms hired 1

J M BURKMAN & ASSOCIATES $290,000 2 filings

Reported by year 1 year

2026 $290,000 2 filings

Issues lobbied 1

Health Issues 2

The count is how many filings named that issue area. A filing reports one lump figure covering every issue on it, so the money above cannot be split between them.

Agencies and chambers lobbied 3

Health & Human Services, Dept of (HHS) 1
HOUSE OF REPRESENTATIVES 1
SENATE 1

Recent filings 2 total

Q2

J M BURKMAN & ASSOCIATES

2nd Quarter (Apr 1 - June 30) 2026 · House · Senate · $290,000 income · posted Jul 17, 2026

View → RR

J M BURKMAN & ASSOCIATES

2nd Quarter (Apr 1 - June 30) 2026 · posted May 27, 2026

View →

Foreign entities disclosed 1

APARTES PHARMACEUTICALS Canada named on 1 filing · highest disclosed ownership 100% · largest disclosed contribution $0

Section 7 of the LD-2: a foreign company or government that owns part of the client, pays toward the lobbying, or benefits from it. Figures are the highest single disclosure across these filings, not a sum: the same stake is re-disclosed each quarter.

Source: federal Lobbying Disclosure Act filings, synced daily. Money is self-reported by the filer and often rounded. Lobbying is legal, disclosed activity.